A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sanofi Japan Targets AI Fluency across Workforce by End-2027
September 16, 2026
-
BUSINESS Mounjaro Label Updated with PIII CV Data Showing Noninferiority
September 16, 2026
-
BUSINESS Moderna Ratchets Up Oncology Drive with Cancer Vaccine PIII Win
September 15, 2026
-
BUSINESS Taiho Takes Small-Molecule Expertise into ADCs; 3-Payload IND Due This Year
September 14, 2026
-
REGULATORY Japan Pharma Investment Subgroup to Hold 1st Meeting September 18
September 14, 2026
-
BUSINESS Former Takeda CEO Yasuchika Hasegawa Dies at 80
September 11, 2026
-
BUSINESS Takeda R&D Chief Plump to Retire in June 2027
September 11, 2026
-
BUSINESS Ex-Takeda CEO Weber Joins Rakuten Medical as Vice Chairman
September 10, 2026
-
REGULATORY MHLW to Weigh Survey Data, Past Approach for FY2027 Revision: Official
September 10, 2026
-
REGULATORY Chuikyo Reps Back Greater Transparency, but Lean toward Broader CEA Price Cuts
September 10, 2026
-
BUSINESS 3 Chugai Researchers Win Lasker Award for Hemlibra Discovery
September 10, 2026
-
BUSINESS Medipal Names Imagawa as New CEO in 1st Leadership Change in 14 Years
September 9, 2026
-
REGULATORY PMDA Generic GMP Inspections a Real-World Test to Stem Startup Risks: Official
September 8, 2026
-
REGULATORY CEA Review Finds Past Decisions Sound, Sees Room for More Transparency
September 8, 2026
-
COMMENTARY As US Pushes Global Cost Rebalancing, Can Japan Answer with Drug Prices?
September 7, 2026
-
REGULATORY LDP Panel Chief Calls for Earlier CGP Coverage in Cancer Care
September 4, 2026
-
BUSINESS Fuji Curbs Shipments of Simponi, Ranmark Biosimilars Soon after Launch
September 4, 2026
-
REGULATORY Japan to Revisit Handling of Steroid Creams under OTC-Like Drug Charge
September 4, 2026
-
ACADEMIA Generic Shortage Response Evolves into Wakayama’s 1st Regional Formulary
September 3, 2026
-
REGULATORY New MHLW Pharma Chief Puts AI in Regulatory Reviews High on Agenda
September 3, 2026
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…